BALCHEM CORP BCPC
Balchem Corporation ("Balchem," the "Company," "we" or "us"), was incorporated in the State of Maryland in 1967. We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
We sell our products through our own sales force, independent distributors and sales agents. Financial information concerning our business, business segments and geographic information appears in Management's Discussion and Analysis of Financial Condition and Results of Operations under Item 7 below and in the Notes to our Consolidated Financial Statements included under Item 8 below, which information is incorporated herein by reference.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.04B | $953.7M | $922.4M | $942.4M | $799.0M | $703.6M | $643.7M | $643.7M | $594.8M | $553.2M |
| Cost of revenue | $666.5M | $617.5M | $620.4M | $661.9M | $555.8M | $479.7M | $432.3M | $439.4M | $405.8M | $372.3M |
| Gross profit | $370.6M | $336.2M | $302.1M | $280.5M | $243.2M | $223.9M | $211.4M | $204.3M | $189.0M | $180.9M |
| R&D | $18.5M | $16.8M | $15.0M | $12.2M | $13.5M | $10.3M | $11.4M | $11.6M | $9.3M | $7.3M |
| SG&A | $67.4M | $67.6M | $53.4M | $55.7M | $41.7M | $43.8M | $36.5M | $28.3M | $28.1M | $27.5M |
| Total operating expenses | $161.3M | $153.3M | $142.9M | $135.3M | $115.7M | $112.8M | $108.8M | $97.2M | $92.1M | $90.0M |
| Operating income | $209.3M | $182.9M | $159.2M | $145.2M | $127.5M | $111.1M | $102.6M | $107.1M | $96.9M | $90.8M |
| Interest expense | — | — | $22.6M | $10.3M | $2.5M | $4.4M | $6.0M | $7.6M | $7.5M | $7.3M |
| Pre-tax income | $199.0M | $166.5M | $137.3M | $133.7M | $125.2M | $106.4M | $96.5M | $99.0M | $88.5M | $82.9M |
| Income tax | $44.2M | $38.0M | $28.7M | $28.4M | $29.1M | $21.8M | $16.8M | $20.5M | $1.6M | $27.0M |
| Net income | $154.8M | $128.5M | $108.5M | $105.4M | $96.1M | $84.6M | $79.7M | $78.6M | $90.1M | $56.0M |
| EPS, basic | 4.80 | 3.97 | 3.38 | 3.29 | 2.98 | 2.63 | 2.48 | 2.45 | 2.83 | 1.78 |
| EPS, diluted | 4.75 | 3.93 | 3.35 | 3.25 | 2.94 | 2.60 | 2.45 | 2.42 | 2.79 | 1.75 |
| Shares, diluted (wtd. avg.) | 32.6M | 32.7M | 32.4M | 32.4M | 32.7M | 32.5M | 32.5M | 32.4M | 32.2M | 31.9M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $74.6M | $49.5M | $64.4M | $66.6M | $103.2M | $84.6M | $65.7M | $54.3M | $40.4M | $38.6M |
| Receivables | $143.6M | $119.7M | $125.3M | $131.6M | $117.4M | $98.2M | $93.4M | $99.5M | $91.2M | $83.3M |
| Inventory | $131.4M | $130.8M | $109.5M | $119.7M | $91.1M | $70.6M | $83.9M | $67.2M | $60.7M | $57.2M |
| Total current assets | $365.6M | $313.8M | $314.2M | $335.8M | $322.2M | $266.9M | $254.9M | $226.3M | $199.3M | $188.4M |
| Property, plant and equipment | $306.6M | $282.2M | $276.0M | $271.4M | $237.5M | $228.1M | $216.9M | $190.9M | $189.8M | $165.8M |
| Goodwill | $816.4M | $780.0M | $778.9M | $769.5M | $523.9M | $529.5M | $524.0M | $448.0M | $441.4M | $439.8M |
| Other intangibles | $133.0M | $132.5M | $191.2M | $213.3M | $94.7M | $121.7M | $143.9M | $109.4M | $128.1M | $147.5M |
| Total assets | $1.69B | $1.58B | $1.60B | $1.62B | $1.20B | $1.17B | $1.16B | $981.4M | $963.6M | $948.6M |
| Short-term debt | — | — | — | — | — | — | $2.5M | $0 | $35.0M | $35.0M |
| Total current liabilities | $176.4M | $157.7M | $148.5M | $140.0M | $143.8M | $94.4M | $92.3M | $82.1M | $108.4M | $101.0M |
| Long-term debt | — | — | — | — | — | — | — | $156.0M | $0 | $226.5M |
| Total liabilities | $428.8M | $425.5M | $543.2M | $686.2M | $322.3M | $337.6M | $412.0M | $289.7M | $346.8M | $427.6M |
| Retained earnings | $1.12B | $997.5M | $897.5M | $814.5M | $732.1M | $656.7M | $590.9M | $528.0M | $464.6M | $388.1M |
| Total equity | $1.26B | $1.15B | $1.05B | $938.3M | $877.0M | $828.2M | $743.7M | $691.6M | $616.9M | $521.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $216.6M | $182.0M | $183.8M | $138.5M | $160.5M | $150.5M | $124.5M | $118.7M | $110.6M | $107.6M |
| Depreciation and amortisation | $45.7M | $48.0M | $54.9M | $51.8M | $48.9M | $51.3M | $45.9M | $44.7M | $44.4M | $46.2M |
| Stock-based compensation | $18.1M | $16.7M | $16.1M | $13.2M | $10.8M | $8.3M | $7.6M | $6.4M | $6.3M | $7.0M |
| Capital expenditure | — | — | — | $49.1M | $36.1M | $32.1M | $25.8M | $19.2M | $27.5M | $23.0M |
| Investing cash flow | -$43.9M | -$59.7M | -$34.8M | -$416.0M | -$35.3M | -$34.6M | -$156.2M | -$32.0M | -$42.7M | -$133.6M |
| Financing cash flow | -$152.8M | -$133.8M | -$153.3M | $246.7M | -$102.2M | -$101.2M | $43.4M | -$71.4M | -$68.6M | -$19.5M |
| Dividends paid | $28.3M | $25.6M | $22.9M | $20.7M | $18.7M | $16.7M | $15.1M | $13.4M | $12.1M | $10.7M |
| Buybacks | $107.6M | $5.7M | $4.5M | $35.4M | $35.2M | $13.5M | $21.3M | $1.4M | $1.9M | $1.6M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-017099.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $553.2M | $594.8M | $643.7M | $643.7M | $703.6M | $799.0M | $942.4M | $922.4M | $953.7M | $1.04B |
| Gross profit | $180.9M | $189.0M | $204.3M | $211.4M | $223.9M | $243.2M | $280.5M | $302.1M | $336.2M | $370.6M |
| Net income | $56.0M | $90.1M | $78.6M | $79.7M | $84.6M | $96.1M | $105.4M | $108.5M | $128.5M | $154.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Results announced Item 2.02
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2800
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SOLS | Solstice Advanced Materials Inc. | $9.44B | 39.9x | 3.1% |
| PRM | Perimeter Solutions, Inc. | $4.55B | — | 16.4% |
| IOSP | INNOSPEC INC. | $2.43B | 21.1x | -3.7% |
| NGVT | Ingevity Corp | $2.39B | — | -2.7% |
| CC | Chemours Co | $1.93B | — | 0.4% |
| OLN | OLIN Corp | $1.78B | — | 3.7% |
| HUN | Huntsman CORP | $1.54B | — | -5.8% |
| ECVT | Ecovyst Inc. | $1.07B | — | 20.9% |